Zealand is positioning the drug as a potential standalone replacement for GLP-1s or as the first medicine that ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...
In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...
JPMorgan analysts initiated coverage on the stock with an overweight recommendation, calling amylin-class medicines such as ...
CagriSema is first in line among a host of drug development projects that rely on amylin; other companies with similar drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback